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Introduction
The knowledge of professionals generally has a half-time of
about 5 years. So half of everything you will read in this
review will be outdated 5 years from now. That may be not
so bad, but it also means that everything you have learned
more than 5 years ago is only half true, and do you know
which half? Keeping up with the literature is an almost
impossible task and never complete. With the introduction
of the new WHO classification at the EAHP/SH workshop
in Bordeaux last year, several major changes are introduced
into our daily work. This will be the subject of review in
the next issue of the Journal of Hematopathology. For now,
there is also quite some interesting data to digest:
Biology of lymphoma
Hodgkin lymphoma
The successful meeting of the EAHP in Bordeaux focused
on tumor microenvironment, an exiting but difficult area.
We know how important the stroma and its cells are for
tumor growth, but the complexity of the interplays between
cells, reporter molecules, and matrix is so large that we
have only limited understanding. We may have to await
further large steps in systems biology to get a grasp of this
by modeling. Nevertheless, interesting work is done in
especially Hodgkin lymphoma (HL), a tumor in which the
environment is remarkably large. Chetaille et al. [1] studied
63 cases of classical HL(cHL) by microarray and found that
EBV-positive cases differed in profile from EBV-negative
cases by the presence of a Th1 response gene signature.
Furthermore, they found that when an overexpression of
genes related to B cells and apoptosis were present, patients
had a favorable outcome. They were able to confirm this by
immunohistochemistry: poorer prognosis in the case of
high percentage of either TIA-1-positive reactive cells or
topoisomerase-2-positive tumor cells, whereas high numb-
ers of BCL11A, FOXP3, or CD20-positive reactive cells
had a favorable influence. Immunodetection of BCL11A, a
marker of both B cells and plasmacytoid dendritic cells, had
the strongest predictive value. EBV-positive cHL (n=108)
was also studied by Asano et al. [2], and in comparison
with age-related EBV-positive B-cell proliferations (n=34),
since also the latter often has an inflammatory background
similar to cHL. cHL had a lower ratio of geographical
necrosis, lower number of cytotoxic T cells, and a better
prognosis. Many more of such studies will be needed
before there will be a reliable marker set that predicts who
of the relatively few patients with cHL will relapse.
B-cell lymphomas
Also in B-cell lymphomas, the microenvironment is subject
of a study: de Jong et al. [3] studied with immunohisto-
chemistry 61 pretreatment biopsies from patients treated in
a clinical trial and found that the prognostic impact was
different for the two treatment arms. CD69 expression on
tumor cells was a poor prognostic sign, and an interfollic-
ular infiltrate of FoxP3-positive T cells was a good
prognostic sign irrespective of the treatment arm, and the
authors suggest that a dense infiltrate of FoxP3-positive T
cells, dense and interfollicular infiltrate of CD68-positive
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were associated with a favorable time to progression in
CVP-treated patients, while being a poor prognostic sign in
fludarabine-treated patients. This finding confirms the
importance of moving away from prognostic marker studies
and go to predictive markers (van Krieken [4]). Ai et al. [5]
did in vivo experiments that partially explain the findings of
de Jong et al.: follicular lymphoma B cells in contrast to
normal B cells could induce conventional T cells to express
FoxP3 and to acquire regulatory function.
The cell of origin in multicentric Castleman disease
(MCD) was hypothesized to be the HHV-8-positive B cell
by Chadburn et al. [6]. The phenotype of this cell was
similar to that of primary effusion lymphomas (PAX5, Bcl-
6-; PRDM1/BLIMP1, IRF4/MUM1+; Ki67+) but varied in
maturation, since in MCD, cells expressed also Oct2 and
cytoplasmic immunoglobulin. Mack and Sugden [7]
showed that EBV and HHV8 are both needed for sustained
cell proliferation in primary effusion lymphomas.
In vitro studies are used to predict efficacy of drugs.
Even though there is often limited correlation with in vivo
studies, these experiments do give insight in the biology of
tumors. Everton et al. [8] studied the effect of rituximab on
the proteasome of follicular lymphoma cells and showed a
change in expression for a multitude of proteins, including
molecules involved in migration, adhesion, signaling,
ubiquitination, and others. Lapalombella et al. [9] combined
two drugs, rituximab and lenolidomide, both as single agent
effective in CLL, and showed that lenolidomide results in
downregulation of CD20 on CLL cells, resulting in lower
efficacy. This results predict that this combination is not
effective in clinical studies. In cell lines of MCL, Jones et
al. [10] showed that a new agent, MI-63, induces p53 and
HDM-2 accumulation and inhibition of proliferation which
was synergistic with m-TOR inhibitors.
Roue et al. [11] were able to show that bendamustine, a
multifunctional alkylating agent, has cytotoxic activity in cell
lines of MCL and CLL and that in p53 mutated cell lines,
there was a synergistic effect with nucleoside analogues.
CyclinD1 overexpression is the hallmark of MCL, and
Dal Col and Colcetti [12] tried to downregulate cyclinD1 in
vivo. They show that inhibition of PI3-K/Akt induces a
40% decrease of cyclin D1 half-life as a result of
accumulation of the dephosphorylated/active form of
GSK-3beta within the nucleus, where this kinase can
phosphorylate cyclin D1. Translocation of cyclin D1 into
the cytoplasm is mediated by the nuclear exportin CRM1,
whose association with cyclin D1 increases following PI3-
K/Akt inhibition. Notably, rapamycin downregulated GSK-
3beta Ser9 phosphorylation with concurrent nuclear export
of cyclin D1 only in MCL cells in which GSK-3beta is
under the control of mTOR. These findings suggest that the
ability to downregulate cyclin D1 through GSK-3beta may
identify subsets of MCL patients who may benefit from the
treatment with mTOR inhibitors.
Two very similar studies show the complexity of the
genetic changes in mantle cell lymphoma (MCL). Both
Schraders et al. and Bea et al. performed combined
genomic and expression profiling. Schraders et al. [13]
used a restricted group of classical mantle cell lymphomas,
whereas Bea et al. [14] used both cell lines and tumors with
different morphologies. Not unexpectedly, this approach
resulted in higher percentages of specific changes in the
Schraders study, pointing to mitochondrial metabolism,
DNA repair, and chromosomal stability, whereas the Bea
paper indicates a great variation of genes in many path-
ways, but often affected in only a minority of the cases. In a
more direct approach, Gelebart et al. [15] investigated the
Wnt pathway in MCL and found it affected in both cell
lines (three out of three) and tumor samples (33 out of 46).
A very different approach for treating MCL patients
might be immunotherapy directed against cyclinD1; this
might be possible since Kondo et al. [16] found in the
blood of MCL patients cytotoxic Tcells directed against the
cyclinD1 positive MCL-cells.
Espinosa et al. [17] studied the NF-kappaB signaling
pathway in diffuse large B-cell lymphoma (DLBL) using
immunohistochemistry for the involved proteins. They
were able to show that NF-kappaB activation is seen in a
minority of cases, that it is generally mediated through the
classical pathway, not associated with the activated B- or
germinal center type and that it predicts good prognosis.
Uddin et al. [18] studied S-phase kinase protein 2
(SKP2), an F-box protein, that targets cycle-dependent
kinase inhibitor p27KiP1 via ubiquitin-mediated degrada-
tion. Using a large number of tissue samples from DLBL
and cell lines, they showed that about 40% of the DLBL
expressed SKP2, which was inversely related to p27Kip1
expression. Treatment of the cell lines with bortezomib
resulted in downregulation of SKP2 and increased expres-
sion of p27Kip1 resulting in increased apoptosis.
Deregulated Myc results in aggressive lymphomas.
Mason et al. [19] investigated in a mouse model the
efficacy of ABT-737, a small molecule that mimics
antagonists of bcl-2 proteins. This drug was effective in
double hit tumors (bcl2 and myc translocation), but not in
myc lymphomas only.
T-cell lymphoma
The knowledge on the biology of T-cell lymphomas is less
than that of B-cell lymphomas, due to the fact that these
tumors are rarer, but also due to the larger complexity of the
T-cell system compared to the B cells. The importance of
the WNT signaling pathway in lymphocyte development
and in many forms of cancer prompted Groen et al. [20]t o
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panel of lymphomas (n=162). In contrast to Gelebart (see
above), they did not find MCL affected, but found nuclear
expression mainly in precursor T-cell malignancy (nine out
of 27) and a few mature T-cell lymphomas, and they
showed gain of function mutation in the gene in a few of
them. In the majority of lesions, however, the WNT
pathway was still functional and thus a potential target for
therapy.
Anaplastic large-cell lymphoma (ALCL) is relatively
well understood, since it has often a translocation involving
the ALK gene. The remarkable morphology of the cells
now seems to be due to the function of the NPM-ALK
fusion gene. Ambrogio et al. [21] showed that the kinase
activity of the nucleophosmin (NPM)-ALK fusion regulat-
ed the shape of ALCL cells. NPM-ALK formed a complex
with the guanine exchange factor VAV1, enhancing its
activation through phosphorylation. VAV1 increased Cdc42
activity, and in turn, Cdc42 regulated the shape and
migration of ALCL cells.
Marzec et al. [22] report that the NPM/ALK-carrying T-
cell lymphoma cells strongly express the immunosuppres-
sive cell-surface protein CD274, as determined on the
mRNA and protein level. Using the small molecule ALK
inhibitor CEP-14083, they were able to inhibit NPM/ALK
function resulting in the downregulation of CD274 expres-
sion. These findings identify an additional cell-transforming
property of NPM/ALK and describe a direct link between
an oncoprotein and an immunosuppressive cell-surface
protein.
The proteasome inhibitor bortezomib is now extensively
studied, since it has the potential of being active in many
forms of cancer. Shen et al. [23] had found earlier that it is
effective in NK-cell neoplasms, and now report that it is
effective in some cell lines at the same doses that is used for
multiple myeloma inducing mitochondrial apoptosis,
whereas in one cell line, a higher concentration was needed,
after which mitotic catastrophe occurred. In the same tumor
type, that is invariable carrying the Epstein–Bar Virus
(EBV), Ian et al. [24] were able to inhibit proliferation by
silencing the EBNA1 gene of the virus.
Epidemiology of lymphoma
Even though there is an improving survival for many forms
of cancer, history of medicine tells us that the discovery of
the cause of a disease is of great importance for the final
solution. Etiological studies in cancer are relatively limited,
and until now, epidemiological studies on risk factors did
use lymphomas as a broad category. Now we know that
lymphomas form a series of different disease entities, and
thus, studies into risk factors should separate the different
forms of lymphoma. Morton et al. [25] did such an analysis
on the more common types, DLBL (although this is likely
not a single entity), follicular lymphoma (FL), marginal
zone lymphoma (MZL), and CLL. They found that late
birth order and high body mass index (≥35 kg/m
2)
increased risk for DLBCL alone. Autoimmune conditions
increased risk for marginal zone lymphoma alone. The
tumor necrosis factor G-308A polymorphism increased
risks for both DLBCL and marginal zone lymphoma.
Exposure to certain dietary heterocyclic amines from meat
consumption increased risk for CLL/SLL alone. There were
no significant risk factors for follicular lymphoma alone.
These data indicate clearly that such studies need to focus
on separate disease entities.
The association of Chlamydia psittaci (CP) with ocular
marginal zone lymphoma is well known. Ponzoni et al. [26]
investigated in 205 extraorbital lymphomas and 135 non-
neoplastic controls the presence of CP by multiple methods.
CP DNA was equally prevalent in nonocular nodal and
extranodal lymphomas: among the latter, it was more
common in diffuse large B-cell lymphomas of the skin (P=
0.03) and Waldeyer’s ring. This important study sheds new
light on the causative role of this microorganism in the
development of lymphomas.
Improving outcome for lymphoma patients is well
described in clinical studies, but those studies include always
a selection of patients. It is therefore important to study
outcome on a population basis. Al-Tourah et al. [27]
investigated the data from the population-based registry of
British Colombia (Canada) and analyzed 600 patients with
newly diagnosed FL. With a median follow-up of
109 months, 170 (28%) developed transformation, 107
(63%) of them based on biopsy confirmation, the others on
clinical parameters. The annual risk of transformation was
3% continuously through 15 years. A multivariate analysis
of clinical factors at diagnosis identified advanced stage as
the only predictor of future transformation. The median
post-transformation survival was 1.7 years. The 5-year
survival was superior for patients with limited extent
transformation compared with those with advanced cases
(66% vs 19%, P<.0001). Clinically diagnosed transforma-
tion has an equal impact on outcome as biopsy proven
transformation.
Many studies are available that describe specific features
of certain lymphoma types in several regions of the world.
By comparing these, one gets further insight in the
background of these lymphoma types, although it is often
difficult to understand what the causes of differences are.
Nomura et al. [28] describe 21 pediatric high-grade B-cell
lymphomas in Papua New Guinea and found a frequent
association with EBV, regardless of subtype, and even in
lymphoblastic lymphoma (LBL). A large series of endemic
Burkitt lymphomas (BL) was described from Uganda by
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6 years and male-to-female ratio was 1.8:1. The age-
standardized incidence was 2.4 per 100,000, being 0.6 in 1–
4 year olds, 4.1 in 5–9 year olds and 2.8 in 10–14 year olds.
Most children presented with abdominal (56%, M/F 1.4:1)
vs. only facial tumors (35%, M/F 3.0:1). Abdominal tumors
occurred in a little older (mean age: 7.0 vs. 6.0 years) and
more frequently in female children (68% vs. 50%). A study
on 234 BL cases from Brazil by Queiroga et al. [30]
revealed that EBV was present in 53% of all BL cases,
varying from 29% (12 out of 42) in the South to 76% (13
out of 17) in the North. The frequency was higher in the
pediatric group. Expression of p53 protein was observed in
16%, and only rare cases showed p63 expression. They
conclude that BL in Brazil is regionally distinct and has a
low incidence of p53 overexpression and a higher-than-
expected association with EBV in sporadic cases.
From Argentina, a series of 40 extranodal oral lympho-
mas was reported by Keszler et al. [31]. Overall mean age
of patients was 49 years, and frequency was greater in
males. The most common location was the gingiva,
followed by the palate. Intraosseous cases were more
frequent in mandible (75%) than in upper maxilla. Of the
cases, 100% were B-cell lymphomas, with a high frequency
of BLBL. Only 60% of the plasmablastic lymphomas in the
series came from HIV+ patients.
Paul et al. [32] describe 56 cases of primary central
nervous system lymphomas from India out of a 19-year
study period. These lymphomas comprised 1% of all
intracranial neoplasms. The patients ranged from 10 to
75 years of age with a median age of 42 years, which is
relatively young. Only one patient was HIV positive. All
cases were diffuse large B-cell lymphomas on histopathol-
ogy except for a single case of CD 3-positive T-cell
lymphoma.
Defining entities
Hodgkin lymphoma
Our understanding of Hodgkin lymphoma has increased
largely but is by far not complete. Using the new insights,
one might forget earlier findings. Benharroch et al. [33]
reviewed their 201 cases of cHL and used strict criteria for
subclassification by which they detected 12 cases of
lymphocyte-depletion. These cases were often EBV posi-
tive and also CD15, although the latter was important in the
original diagnosis. To increase the understanding of the
relatively rare nodular lymphocyte predominant HL, Brune
et al. [34] performed expression array analysis on micro-
dissected L&H cells and compared the results to those of
normal B cells and B cells from other lymphoma types.
There was a very high similarity to the tumor cells from T-
cell-rich B-cell lymphoma as well as cHL, with partial loss
of B-cell phenotype and altered expression of many genes
involved in cancerogenesis.
B-cell lymphomas
Most follicular lymphomas (FL) present in lymph nodes,
but extranodal presentation may occur. Weinberg et al. [35]
compared 27 extranodal FL to 44 nodal cases, and in
addition, eight cutaneous follicle center cell lymphomas,
known to be a different entity. Extranodal cases were more
often diffuse, lacked CD10 expression and had, surprising-
ly, more often t(14;18), especially the minor breakpoint.
Follow-up was quite similar between the groups. This paper
points to the difficulty of the use of many criteria (clinical,
morphological, phenotypical, genetic) to make a diagnosis,
and then use the same criteria as prognosticator or as single
criterium.
Two studies deal with ocular/orbital lymphomas, Lagoo
et al. [36] focusing on pathological features, Sjo et al. [37]
on more clinical aspects. This relatively rare lymphoma is
not always easy to diagnose and classify, since it often has
not the typical features of MZL compared to gastric cases.
Only a minority of the cases has a translocation that
involves the MLT gene (15% in the USA study, 5% in the
Danish study). About 25% of the patients have disseminat-
ed disease, and 5-year survival is about 75%.
Takino et al. [38] collected cutaneous MZL from Asia,
Germany, and the USA; in total, 60 cases and showed that
they have fairly common clinical and pathologic features.
In nine out of 25 Asian cases, there was tissue
eosinophilia, which was virtually absent in the Western
cases. In no case was Borrelia or the MALT1-API2 fusion
found.
Quite some work is done on the detection of a molecular
marker for MZL. It is already well known that several
translocations leading to NFkappaB activation occur in
extranodal MZL. Vinatzer et al. [39] studied 29 cases from
different sites with several cytogenetic methods and
document the following: balanced translocations were
found in 21 cases. IGH was rearranged in the majority of
cases with balanced translocations (n=17/21); three cases
had t(11;18)/API2-MALT1, and one case had novel t(6;7)
(q25;q11), respectively. IGH partner genes involved
MALT1, FOXP1, BCL6, and four new chromosomal
regions on chromosome arms 1p, 1q, 5q, and 9p. LDI-
PCR identified three novel partner genes on 1p (CNN3), 5q
(ODZ2), and 9p (JMJD2C). FISH assays were established
and confirmed LDI-PCR results. QRT-PCR showed dereg-
ulation of the novel genes in the translocation-positive
cases. These findings underline the molecular heterogeneity
of MZL and also demonstrate that presently molecular
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colorectal and gastric cases and found MLT translocation in
two out of nine cases and CpGisland methylation (CIMP)
eight out of 13 cases. The CIMP-positive cases had a
poorer survival. Chanudet et al. [41] used high-resolution
chromosome 6 tile-path array-CGH which identified NF-
kappaB inhibitor A20 as the target of 6q23.3 deletion and
TNFA/B/C locus as a putative target of 6p21.2–22.1 gain.
Interphase fluorescence in situ hybridization (FISH)
showed that A20 deletion occurred in MALT lymphoma
of the ocular adnexa (8/42=19%), salivary gland (2/24=
8%), thyroid (1/9=11%), and liver (1/2), but not in the lung
[26], stomach [45], and skin [13]. A20 deletion and TNFA/
B/C gain were significantly associated and exclusively
found in cases without characteristic translocation. In ocular
cases, A20 deletion was associated with concurrent in-
volvement of different adnexal tissues or extraocular sites at
diagnosis, a higher proportion of relapse (67% versus 37%),
and a shorter relapse-free survival.
Lymphoplasmacytic lymphoma (LPL) is difficult to
separate from MZL. Sargent et al. [42] studied 17 nodal
LPL which were divided into classic (n=5), vaguely
nodular (n=5), and others (n=7). They were able to show
that among the classic LPL, four out of four had an IgM
paraproteinemia, five out of five had bone marrow
involvement (BM+), and one out of five had +MALT1.
One of one vaguely nodular LPL had an IgM paraprotein,
two out of four were IgM+, two out of four IgG+, one out
of three had BM+, and one out of five had an IgH
rearrangement. Among the other cases, two out of three had
a paraprotein, two out of seven were IgM+, five out of
seven IgG+, and zero out of three had BM+. Of these cases,
one showed +12, one +18, and one IgH/BCL2 translocation
plus +18. None of the 17 cases had a 6q21 deletion or +3.
These results are quite different from those obtained
generally in MZL, but the genetic data differ also from
those seen in bone marrow-derived LPL.
Although FL is characterized by t(14;18), not all cases
carry the translocation. Gaqyi et al. [43] collected bcl-2
negative (translocation and protein) FL and studied the
mutational status of the IgH gene, but did not find
differences compared to bcl2-positive cases. Additional
genetic alterations are common in FL. d’Amore et al. [44]
found in t(14;18) positive cases in initial and follow-up
biopsies of 360 patients +7, del(6q), +der(18) t(14;18), +18,
and +X as the common alterations, multiple clones were
common, and genetic divergence was found especially in
follow-up biopsies.
Since MUM1 is overexpressed in the activated type of
DLBL, Hunt et al. [45] investigated whether MUM1 is
translocated in these tumors. In one out of 16 cases, a
MUM1 break was detected, and none of 17 germinal
center-type DLBL carried the break.
Burkitt lymphoma (BL) is defined by morphology,
phenotype, and MYC translocation, but Leucci et al. [46]
describe in a series of bona fide endemic (African) BL that
five out of 35 cases did not have a break in the MYC gene
that could be detected by a split signal probe covering the
gene, and using fusion probes, no juxtaposition to immu-
noglobulin genes was detected either. In these cases, the
miRNA hsa-mir-34b was downregulated, and in in vivo
studies this miRNA could regulate MYC expression,
providing an alternative pathway in MYC-negative BL.
Such cases were not included in the expression and CGH
array studies by Salivierra et al. [47]. In the array study, it
was shown that pediatric and adult cases of Burkitt
lymphoma have similar genetic alterations but that DLBL
that are similar to BL using expression array have different
genetic backgrounds. These data confirm that expression
arraying is not a tool to be used in the classification of
tumors.
T-cell lymphomas
Regulatory T cells are a relatively recent recognized subset
of T-lymphocytes, expressing FoxP3 (although not exclu-
sively). Bonzheim et al. [48] investigated whether subtypes
of T-cell lymphomas were derived from these cells but
detected among anaplastic large cell lymphomas (ALCL),
angioimmunoblastic T-cell lymphomas (AILD), and pe-
ripheral T-cell lymphomas (PTCL) only one such case,
which was rapidly progressive.
T-cell lymphomas are molecularly less characterized
compared to B-cell lymphomas. Feldman [49] performed
an important study in which the multiple myeloma
oncogene-1/interferon regulatory factor-4 (IRF4) locus
was analyzed by FISH. IRF4 translocations are known to
exist in myeloma and some B-cell lymphomas, but were not
yet studied in PTCLs. Among 169 PTCLs, 12 cases had
IRF4 translocations. Two cases with t(6;14) (p25;q11.2)
had translocations between IRF4 and the T-cell receptor-
alpha (TCRA) locus. Both were cytotoxic PTCLs,
involving bone marrow and skin. Eight of the remaining
ten cases were cutaneous anaplastic large-cell lympho-
mas (ALCLs) without TCRA rearrangements (57% of
cutaneous ALCLs tested). These findings demonstrate
that IRF4 translocations are a recurrent genetic abnor-
mality in PTCLs. Cytotoxic PTCLs involving bone
marrow and skin and containing IRF4/TCRA trans-
locations might even represent a distinct clinicopatho-
logic entity.
A key feature of enteropathy-associated T-cell lympho-
ma is the loss of surface CD3 with remaining cytoplasmic
expression. Using a cell line derived from such a
lymphoma, Tjon et al. [50] were able to determine the
mechanism responsible for this: defective assembly or
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confirmed in two other patients.
ALCL is defined by CD30 expression and morpholog-
ical features, but the latter may be misleading in some
cases. Bovio and Allen [51] determined by flow cytometry
the expression profile of 20 ALCL, nine ALK1 positive, 11
negative. Almost all cases expressed at least one T-cell-
associated antigen. CD13 and CD33 were expressed in all
ALK1 positive cases, but in only 1 Alk1 negative case.
Misinterpretetion for myeloid sarcoma should be avoided in
the positive cases.
Kong et al. [52] did an extensive analysis of 22 Asian
cases of subcutaneous panniculitis-like T-cell lymphoma.
Unusual features were found in two cases, namely, CD8
negative. CD30 was negative in all cases, and CD56 was
focally positive in two cases. EBV was present in one case.
All cases were clonal using the Biomed 2 primer sets. Cases
with angioinvasion were more aggressive.
The immunophenotype of 84 cases of nasal-type extra-
nodal NK/T cell lymphoma was studied using TMA’sb y
Schwartz et al. [53]. CD2 was positive in 93%, CD3 in
84%, CD5 in 27%, CD56 in 58%, granzyme in 71%,
perforin in 86%, TIA1 in 90%, CD30 in 35%, and EBV in
87%; CD20 was absent in all cases.
Cutaneous lymphomas
Cutaneous lymphomas remain an extensively studied
group, especially compared to its relatively rarety. Riou-
Gotta et al. [54] described 71 cases from a population-based
registry in France, covering the period from 1980 to 2003.
Of the cases, 82% were of T-cell origin (the majority
mycosis fungoides; MF), and thus, 18% were B-cell
lymphomas. There was an increase in incidence from 0.2
to 0.7/100.000 and 5 year survival was about 65% for MF
and also for the other types taken together.
Van Maldegem [55] underlined that cutaneous lympho-
mas are different from lymphomas from other sites, also
molecularly. They studied an extensive panel of primary
cutaneous MZLs and show that these are different com-
pared to other extranodal MZL. Whereas most noncuta-
neous MZLs express IgM, cutaneous MZLs in majority
express IgG, IgA, and IgE. Furthermore, these isotype-
switched cases lack CXCR3 and seem to arise in a different
inflammatory environment.
Granulomatous slack skin disease (GSS) and granulo-
matous MF are rare and puzzling. Kempf et al. [56]
collected four cases of the former and 15 of the latter.
These cases were diagnosed according to the WHO
classification. There was little epidermotropism, and treat-
ment was not successful in most cases, and one third of the
patients died of their disease. Why granulomas occur
remains unknown.
New entities/subtypes
Like many immunodeficiencies is the Nijmegen breakage
syndrome associated with lymphoproliferations.
Gladkowska-Dura et al. [57] described their experience
from 105 such patients, of whom half developed a
lymphoproliferation. From 14 patients, the pathology is
described. Most commonly, DLBL and T-LBL/ALL were
present, and all had a clonal disease. Using split signal
probes breaks in Ig and TCR genes were commonly
detected, indicating that the repair defect is indeed
responsible for the development of lymphoproliferations.
The description of the pathology in IgG4 disease
becomes extensive. Sato et al. [58] collected experience
on ocular lesions from 21 patients. In 17 of them, the
lacrimal gland was involved, the conjunctiva in no patient.
There was a dense, fibrotic plasmacellular infiltrate with
IgG4 expression. In two out of 17, the proliferation was
clonal.
The subtyping of DLBL is of continuous interest. Lenz
et al. [59] performed an analyses of 203 cases combining
expression and CGH array. They were able to show that the
three subgroups, germinal center B-cell-like (GCB), acti-
vated B-cell-like (ABC), and primary mediastinal (PMB)
had different patterns of genomic changes, but no specific
alterations were found. INK4a/ARF was commonly delet-
ed, and FoxP1 upregulated in the ABC group. In the GBC
group, amplification of mir-17-92 and deletion of PTEN
were often seen.
Wong et al. [60] analyzed 32 DLBL of the upper
aerodigestive tract using immunohistochemistry and found
a similar distribution for ABC and GBC cases compared to
other sites and EBV in only one patient. They conclude that
DLBL from this site is not a specific entity.
Dunphy et al. [61] detected a case of PMB with t(14;18)
and analyzed 24 cases in detail using FISH, PCR, and
immunohistochemistry. Four of the cases had features that
are associated with germinal center origin, and these might
form a subset of this entity.
The role of EBV in lymphoproliferations in immune-
deficient patients is well known. Increasingly, EBV is being
recognized in lymphomas from patients with no clear
immune deficiency, especially in the elderly. Kleinschmidt
et al. [62] describe four patients with central nervous
system lymphomas that were on imaging suggestive for
EBV-associated cases and who had been treated with a
variety of immune suppressive drugs. Since the association
is not well known, and pathologists are not always well
informed, the authors suggest that EBV testing should be
done more often.
Ketzenberger et al. [63] described a series of 35 FL with
predominantly diffuse growth pattern. Almost all of the
cases lacked the t(14;18) but had a typical immunopheno-
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profile of four of the cases was studied and comparable
with more classic FL. The patients had often low-stage
disease and 27 out of 29 cases had a 1p36 deletion, all in all
suggesting that this may represent a separate (sub)entity.
The testis and the central nervous system are considered
as immune-privileged sites, and DLBL arising in these sites
(IP-DLBL) have some special features. Booman et al. [64]
performed a gene expression and CGH-array study on 15
central nervous system (CNS) cases, nine testicular cases,
and 15 nodal DLBL, which revealed that loss of 6p21.32–
p25.3, including the HLA genes was associated with both
types of IP-DLBCL, whereas gain of 2p16.1–p25.3 was
associated with nodal DLBCL. Gain of 12q15–q21.1 and
12q24.32–q24.33 was associated with CNS DLBCL and
gain of 19q13.12–q13.43 with testicular DLBCL. Analysis
of candidate genes in site-specific regions and minimal
common regions revealed two major groups of genes: one
involved in the immune response, including regulation of
HLA expression, and the other involved in apoptosis,
including the p53 pathway. The presence of both shared
and site-specific aberrations in CNS and testicular DLBCLs
underlines the concept of IP-DLBCL but also indicates that
IP-DLBCLs of the CNS and testis do not form a single
entity.
DLBL from extranodal sites have generally a better
outcome than nodal cases. This was confirmed by Sato et
al. [65] who studies oral cases (excluding tonsillar ones),
even though 17 out of 21 cases were of ABC type as
determined by immunohistochemistry.
A recently described lesions is atypical lymphocytic
panniculitis (ALLP). Magro et al. [66] describe seven such
patients who have waxing and waning placques. Since a
continuum with subcutaneous panniculits like T-cell lym-
phoma had been suggested, they performed clonality
testing, and all lesions were clonal, and the clones detected
were preserved in follow-up biopsies. This situation, very
similar to refractory celiac disease, and also monoclonal
gammopathy of undetermined significance points to the
importance of interpretation of clonality testing in the
complete clinicopathologic setting.
Akiyama et al. [67] describe five cases of CD8+, CD56+
T-cell lymphoma in the small intestine, while the patients
lack enteropathy. There was no EBV, and the TCR was
clonally rearranged, and the clinical course was dismal.
These tumors seem closely related to EATL.
After seeing two cases of ALCL in the breast of women
who had silicone implants, de Jong et al. [68] performed a
national case-control study in the Netherlands. In 16 years
11 primary ALCL in the breast had been diagnosed, and
five of these were in women with implants. In women with
other primary breast lymphomas, only one had an implant.
These data suggest that breast implants have a small but
significant risk for developing ALCL. Another unusual
presentation of ALCL was discovered by Mosunjac et al.
[69] who analyzed five autopsy-detected ALCL cases.
These patients had had a rapid clinical problem that was
reminiscent of sepsis or fever of unknown origin and lacked
lymphadenopathy. These cases had extranodal involvement
and often hemophagocytosis.
Rodriquez-Pinilla et al. [70] collected 146 cases of T-cell
lymphoma to investigate the cell of origin. First, they
looked for PD-1-positive cases which were classified as
AILT, known to be derived from follicular helper T cells.
The other cases were studied by TMA using a wide panel
of markers and EBV; of the non-AILT cases almost 30%
expressed PD-1 as well and many of these expressed other
follicular helper T-cell markers also (CXCL13, bcl6,
CD10). The authors suggest that the spectrum of AILT may
be wider than previously thought but also that other types of
T-cell lymphoma may be derived from follicular T cells.
Pitfalls in lymphoma diagnosis
Pathologists recognize that lymphoma classification
requires special expertise. LaCasce et al. [71] investigated
whether the WHO-classification has facilitated the correct
diagnosis of lymphomas by evaluating the results from their
referred cases. For this analysis they focused on the five
most common entities and found that the discordancy rate
was 6%, with the most discordancies due to grading FL.
The majority of discordant cases (80%) might have had a
different treatment. Since less common lymphomas total
generally up to about 20–25% of all cases, this study favors
review of lymphoma even in this era of WHO classification
and many ancillary techniques.
Castleman’s disease remains an enigmatic lesion with a
variable morphology. Based on 11 cases, Kojima et al. [72]
describe the different types of follicles one may encounter
in Castleman’s disease and delineate the sometimes difficult
differential diagnosis with reactive lesions on the one side,
and HL on the other.
Cancer cells do not behave like normal cells and
therefore unusual expression of markers can occur. Wang
et al. [73] report four cases of CD-3 positive B-cell
lymphomas and Rahemtullah et al. [74] nine cases of
CD20-positive T-cell lymphomas, stressing the need for
double positive and negative markers for lineage determi-
nation in malignant lymphoproliferations.
Prognostic factors in lymphoma
Investigations into prognostic factors remain popular. Quite
a series of papers on this topic were published, and only a
56 J Hematopathol (2009) 2:50–61small sample of results is given. None of the studies were
confirmatory in nature, and those are the only ones in
which clinical application can be found. Schreck et al. [75]
demonstrate that a large number of Th2 cells in HL is
related to better survival; Dong et al. [76] show that bcl10
expression (next to t(11;14)) is related to HP-eradication
unresponsiveness; according to Wang et al. [77], cytoplas-
mic sox11-expressing MCLs have a poorer survival;
mutation nor polymorphism of the CD20 gene is predicting
rituximab response (Sar et al. [78]); Aktas et al. [79] show
that high apoptotic index is related to good prognosis in
pediatric lymphomas; Lenz et al. [80] describes new gene
signatures that predict therapy response in DLBL; Peh et al.
[81] found that bcl-6 expression is associated with poor
survival in DLBL and immunohistochemically determined
ABC not; according to Johnson et al. [82], DLBL with low
CD20 expression havelower survival rate; Ki67 and Pim1 are
independent indicators of poor survival in MCL (Hsi et al.
[83]); low Ki67 is a negative predictor of survival in DLBL
(Hasselblom et al. [84]); SIRT1 expression is associated with
poor prognosis in DLBL (Jang et al. [85]); in FL, Johnson et
al. [86] show that secondary genetic alterations indicate
aggressive behavior; Hasselblom et al. [87]s h o wt h a tt h e
number of CD68-positive cells in DLBL does not predict
prognosis; TCL1A is associated with more aggressive
clinical behavior in CLL and MCL according to Aggarwal
et al. [88]; aberrations in the MYC locus are associated with
poor outcome in DLBL (Klapper et al. [89] and Yoon et al.
[90]); expression of P-glycoprotein indicates therapy unre-
sponsiveness in nasal type NK/Tcell lymphoma according to
Wang et al. [91];
Ancilliary techniques
Flow cytometry is increasingly used for the phenotyping of
lymphomas, but HL is often difficult to recognize due to the
scarcity of tumor cells. In a large study using flow
cytometry of 76 HL and 156 reactive lymph nodes,
Seegmiller et al. [92] showed that HL can be suggested
by the presence of many CD7- and CD4-positive cells.
Using the same technique, Pierson et al. [93] show that
aberrant CD26 expression indicates, together with other T-
cells markers, T-cell lymphoma, but it is not specific.
FISH is now commonly used for the detection of
aberrations in specific genes. De Rijk et al. [94] describe
a robust paraffin tissue approach using split signal probes,
tested in eight different laboratories using 16 different
probes covering the most important regions involved in
translocation in lymphomas. This method uses tissue
sections, so that even small areas of tumor can be evaluated
without microdissection. Using isolated nuclei paraffin
embedded tissue from 20 cases of CLL, Flanagan et al.
[95] were able to determine almost all aberrations detected
in blood samples. Huh et al. [96] used this method for
staging on bone marrow aspirates and showed that FISH is
more sensitive than classic cytogenetics, but no correlation
with immunohistochemistry was done.
Clonality testing is nowadays an important tool in the
management of lymph node biopsies, but is prone to
mistakes. Groenen et al. [97] use a case-based approach to
describe common pitfalls in the interpretation of TCR
clonality testing and reiterate the importance of interpreta-
tion of the molecular results in the context of the
histological and immunohistochemical findings.
Santon et al. [98] performed clonality testing on gastric
biopsies from 19 patients treated for gastric MZL and found
persistent clonality even though histology did not show
lymphoma anymore. This was especially the case in tumors
with t(11;14). The clinical meaning of this finding is not yet
clear.
Morales et al. [99] tackle the difficult problem of
separating reactive (n=23) form malignant (n=26) B-cell
proliferations in the skin, using the Biomed set of primers.
In patients with a lymphoma, a clone was detected in 85%
of the samples, and in only 4% of the reactive infiltrate was
the data very promising.
Tan et al. [100] analyzed the occurrence of B-cell
clonality in 74 T-cell lymphomas. Using the Biomed
approach, 86% had a clonal TCR, and 8% a concurrent
clonal B-cell rearrangement. There was no association with
the presence of EBV.
Cytology obtained from fine needle aspirates (FNA) is a
limited invasive option for diagnosing lymphomas but has
limitations. Pai et al. [101] used FNA-obtained cells for
morphology, phenotyping, and molecular tests to evaluate
enlarged lymph nodes in patients with mycosis fungoides.
In seven out of ten patients, they could determine the
presence of tumor cells in the lymph node; three of them
had large-cell transformation. Remarkably, two of the
patients had HL in the lymph node. This study shows
possibilities of FNA in an experienced setting.
Also, multicolor FISH is possible on FNA material as
shown by Caraway et al. [102]. In 49 out of 50 patients
with CLL, they were able to obtain data on genetic
aberrations, with similar prognostic impact as known from
traditional studies.
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